Pharmaceutical composition for treating rheumatoid arthritis, preparation method and application thereof

Abstract

The invention provides a pharmaceutical composition for treating rheumatoid arthritis, a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The pharmaceutical composition is a preparation prepared from the following raw material medicines in parts by weight: 8-20 parts of astragalus membranaceus, 3-12 parts of honey-fried licorice root, 3-20 parts of caulis spatholobi, 3-15 parts of radix paeoniae alba, 3-15 parts of radix angelicae pubescentis, 3-12 parts of pericarpium citri reticulatae, 3-12 parts of angelica sinensis, 3-12 parts of zaocys dhumnade, 1-6 parts of scorpion, 3-12 parts of radix angelicae, 1-9 parts of honeycomb, 3-20 parts of herba epimedii, 3-15 parts of radix clematidis, 3-20 parts of semen cuscutae, 1-12 parts of tripterygium wilfordii, 3-25 parts of semen coicis, 3-25 parts of scorched hawthorn fruit and 3-25 parts of Chinese yam. According to the invention, all the medicinal materials of the composition are precise and appropriate in compatibility, play a synergistic effect together, have the effects of tonifying the kidney, dredging collaterals, dispelling wind, relieving pain and removing dampness to relieve pain, can treat arthralgia, joint swelling and pain, waist and knee pain, flaccidity and weakness, unfavorable flexion and extension of limbs or numbness, hand and foot contracture and qi and blood stagnation, and have a good treatment effect on rheumatoid arthritis and low recurrence rate; and the pharmaceutical composition is low in cost and excellent in application prospect.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for treating rheumatoid arthritis, a preparation method and application thereof. Background technique [0002] Rheumatoid arthritis (RA) is a chronic systemic disease of unknown etiology mainly characterized by inflammatory synovitis. Autoimmune disease with erosive arthritis as the main symptom. It is characterized by polyarticular, symmetrical, and aggressive arthritis of the small joints of the hands and feet, often accompanied by involvement of extra-articular organs and positive serum rheumatoid factor, which can lead to joint deformities and loss of function. The pathogenesis of RA may be related to heredity, infection, and sex hormones. The pathology of RA arthritis mainly includes the proliferation of synovial lining cells, the infiltration of a large number of inflammatory cells in the interstitium, the neogenesis of ...

AI Technical Summary

Problems solved by technology

Patent CN1362068A discloses a drug for treating rheumatoid arthritis with black snake, scorpion, epimedium, tripterygium wilfordii, Aconitum aconitum, etc. as raw materials. The drug can improve microcirculation, enhance spine, joints and their surrounding areas The blood supply of the tissue can promote the absorption of inflammation in the spine, joints and surrounding tissues, and reduce the accumulation of pain-causing substances, but the effect still needs to be further improved

Patent CN104523972A discloses a pharmaceutical composition for treating rheumatoid arthritis, which also has a certain effect on rheumatoid arthritis, but it involves expensive drugs such as pangolins, and the cost is high

[0005] It can be seen that the drugs for the treatment of rheumatoid arthritis in the prior art have problems such as insufficient effect and high cost